Compare Charles River Laboratories Intl. Inc (CRL) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Lennar Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $227.4 (market cap $11.14B), while Lennar Corporation trades at $85.15 (market cap $20.12B). The key difference: Lennar Corporation is the larger of the two by market cap, and Lennar Corporation pays a 2.39% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | LEN | |
|---|---|---|
Market Cap | $11.14B | $20.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $142.40 |
52-Week Low | $145.57 | $82.30 |
Enterprise Value | $14.00B | $24.00B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Lennar Corporation (LEN) trades at $82.84, down 1.7% on the day, with technical indicators showing bearish momentum despite oversold RSI conditions. The stock faces fundamental pressure from declining revenue and net income margins, which fell to 6.07% in 2025 from 13.7% in 2022. Recent earnings misses and housing affordability challenges create headwinds, though analyst consensus remains positive with a $84.38 price target.
LEN presents a value opportunity with attractive valuation multiples (P/E 12.98, P/B 0.92) but faces execution risks amid declining profitability. The housing market's sensitivity to mortgage rates and competitive pressures require careful monitoring. Upside potential exists if operational improvements and housing policy support materialize, making this suitable for patient investors comfortable with cyclical exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
